Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of Reduced Renal Mass
The DOI matches its Crossref record.
Abstract
Many kidney transplant patients experience an increase in proteinuria when converted from a calcineurin inhibitor-based regimen to one based on a mammalian target of rapamycin (mTOR) inhibitor, and preexisting proteinuria and poor renal function have been identified as risk factors for this increase. Our aim was to evaluate the effect of sirolimus, an mTOR inhibitor, on renal function and histology in a proteinuric model of reduced renal mass. Sirolimus-treated animals had approximately half as much proteinuria as vehicle-treated animals (P < 0.05), and had less glomerulosclerosis, tubular atrophy, interstitial fibrosis, and inflammation. Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2. In conclusion, sirolimus halted the progression of proteinuria and structural damage in a rat model of reduced renal mass, possibly through a reduction in renal VEGF activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Lieberthal, W., & Levine, J. S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111186 · Cited by 280
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Cyclin G1 and TASCC regulate kidney epithelial cell G 2 -M arrest and fibrotic maladaptive repair
Canaud, G., Brooks, C. R., Kishi, S., Taguchi, K., Nishimura, K., Magassa, S., Scott, A., Hsiao, L.-L., Ichimura, T., Terzi, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4754 · Cited by 139
“Introducing these inhibitors early after the injury (28) is associated with worsening kidney lesions, whereas administration later is associated with improvement of fibrosis and tubular dilation (30, 32).”
BackgroundZeng, C., Fan, Y., Wu, J., Shi, S., Chen, Z., Zhong, Y., Zhang, C., Zen, K., & Liu, Z. (2014) · The Journal of Pathology · doi:10.1002/path.4382 · Cited by 80
Temiz-Resitoglu, M., Kucukkavruk, S. P., Guden, D. S., Cecen, P., Sari, A. N., Tunctan, B., Gorur, A., Tamer-Gumus, L., Buharalioglu, C. K., Malik, K. U., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.034 · Cited by 77
“Indeed, there is little information about the role of mTOR in the regulation of blood pressure in the literature (Diekmann et al., 2007; Yang et al., 2007).”
Background
Metadata
- Authors
- Diekmann, F., Rovira, J., Carreras, J., Arellano, E. M., Ban[Combining Tilde]o[Combining Acute Accent]n-Maneus, E., Rami[Combining Acute Accent]rez-Bajo, M. A. A. J. A. A., Gutie[Combining Acute Accent]rrez-Dalmau, A., Brunet, M. G. A., & Campistol, J. M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-10
- Volume
- 18
- Issue
- 10
- Pages
- 2653-2660
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151396528
- Cited by
- 54
- References
- 0
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.